{"id":846846,"date":"2025-05-05T17:18:33","date_gmt":"2025-05-05T21:18:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/"},"modified":"2025-05-05T17:18:33","modified_gmt":"2025-05-05T21:18:33","slug":"halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/","title":{"rendered":"Halozyme to Participate in the BofA Securities 2025 Healthcare Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN DIEGO<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">May 5, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Halozyme Therapeutics, Inc. (NASDAQ: HALO) (&#8220;Halozyme&#8221;) today announced that Dr. <span class=\"xn-person\">Helen Torley<\/span>, president and chief executive officer, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference.<\/p>\n<p>The presentation is scheduled for <span class=\"xn-chron\">Tuesday, May 13<\/span> at <span class=\"xn-chron\">4:20pm PT<\/span> \/ <span class=\"xn-chron\">7:20pm ET<\/span>.<\/p>\n<p>A live audio webcast will be available on the Investor Relations section of the Company&#8217;s website. Replays of the audio webcasts will be available for 90 days following the conference.<\/p>\n<p>\n        <b>About Halozyme<\/b>\n      <\/p>\n<p>Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE<sup>\u00ae<\/sup> drug delivery technology with the proprietary enzyme rHuPH20, Halozyme&#8217;s commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE<sup>\u00ae<\/sup> technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.<\/p>\n<p>Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex<sup>\u00ae<\/sup> and XYOSTED<sup>\u00ae<\/sup>, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.<\/p>\n<p>Halozyme is headquartered in <span class=\"xn-location\">San Diego, CA<\/span> and has offices in <span class=\"xn-location\">Ewing, NJ<\/span> and <span class=\"xn-location\">Minnetonka, MN.<\/span><span class=\"xn-location\">Minnetonka<\/span> is also the site of its operations facility.<\/p>\n<p>For more information visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4420421-1&amp;h=2912007738&amp;u=https%3A%2F%2Fwww.halozyme.com%2F&amp;a=www.halozyme.com\" target=\"_blank\" rel=\"nofollow\">www.halozyme.com<\/a>\u00a0and connect with us on LinkedIn and Twitter.<\/p>\n<p>\n        <b>Contacts:<\/b>\n      <\/p>\n<p>Tram\u00a0Bui<br \/>VP, Investor Relations and Corporate Communications<br \/>609-359-3016<br \/><a href=\"mailto:tbui@halozyme.com\" target=\"_blank\" rel=\"nofollow\">tbui@halozyme.com<\/a><\/p>\n<p>\n        <span class=\"xn-person\">Samantha Gaspar<\/span><br \/>\n        <br \/>Teneo<br \/>212-886-9356<br \/><a href=\"mailto:samantha.gaspar@teneo.com\" target=\"_blank\" rel=\"nofollow\">samantha.gaspar@teneo.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder3314\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg\" title=\"Halozyme Therapeutics, Inc. Logo. (PRNewsFoto\/Halozyme Therapeutics, Inc.) (PRNewsfoto\/Halozyme Therapeutics, Inc.)\" alt=\"Halozyme Therapeutics, Inc. Logo. (PRNewsFoto\/Halozyme Therapeutics, Inc.) (PRNewsfoto\/Halozyme Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA80324&amp;sd=2025-05-05\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference-302446419.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference-302446419.html<\/a><\/p>\n<p>SOURCE  Halozyme Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA80324&amp;Transmission_Id=202505051715PR_NEWS_USPR_____LA80324&amp;DateId=20250505\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO , May 5, 2025 \/PRNewswire\/ &#8212; Halozyme Therapeutics, Inc. (NASDAQ: HALO) (&#8220;Halozyme&#8221;) today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13 at 4:20pm PT \/ 7:20pm ET. A live audio webcast will be available on the Investor Relations section of the Company&#8217;s website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE\u00ae drug delivery technology with the proprietary enzyme rHuPH20, Halozyme&#8217;s commercially-validated &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Halozyme to Participate in the BofA Securities 2025 Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-846846","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO , May 5, 2025 \/PRNewswire\/ &#8212; Halozyme Therapeutics, Inc. (NASDAQ: HALO) (&#8220;Halozyme&#8221;) today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13 at 4:20pm PT \/ 7:20pm ET. A live audio webcast will be available on the Investor Relations section of the Company&#8217;s website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE\u00ae drug delivery technology with the proprietary enzyme rHuPH20, Halozyme&#8217;s commercially-validated &hellip; Continue reading &quot;Halozyme to Participate in the BofA Securities 2025 Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-05T21:18:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Halozyme to Participate in the BofA Securities 2025 Healthcare Conference\",\"datePublished\":\"2025-05-05T21:18:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\\\/\"},\"wordCount\":357,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\\\/\",\"name\":\"Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\",\"datePublished\":\"2025-05-05T21:18:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Halozyme to Participate in the BofA Securities 2025 Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - Market Newsdesk","og_description":"PR Newswire SAN DIEGO , May 5, 2025 \/PRNewswire\/ &#8212; Halozyme Therapeutics, Inc. (NASDAQ: HALO) (&#8220;Halozyme&#8221;) today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13 at 4:20pm PT \/ 7:20pm ET. A live audio webcast will be available on the Investor Relations section of the Company&#8217;s website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE\u00ae drug delivery technology with the proprietary enzyme rHuPH20, Halozyme&#8217;s commercially-validated &hellip; Continue reading \"Halozyme to Participate in the BofA Securities 2025 Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-05T21:18:33+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Halozyme to Participate in the BofA Securities 2025 Healthcare Conference","datePublished":"2025-05-05T21:18:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/"},"wordCount":357,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/","name":"Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","datePublished":"2025-05-05T21:18:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-bofa-securities-2025-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Halozyme to Participate in the BofA Securities 2025 Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/846846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=846846"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/846846\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=846846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=846846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=846846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}